Fusion Antibodies plc Share Price

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Delayed London S.E. 13:32:41 30/04/2024 BST 5-day change 1st Jan Change
3.3 GBX -7.04% Intraday chart for Fusion Antibodies plc -13.16% -22.35%

Financials

Sales 2024 * 1.15M 1.44M 115M Sales 2025 * - Capitalization 3.39M 4.24M 339M
Net income 2024 * -1M -1.25M -100M Net income 2025 * - EV / Sales 2024 * 2.94 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.27 x
P/E ratio 2025 *
-
Employees 48
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.63%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.04%
1 week-13.16%
Current month-12.00%
1 month-14.29%
3 months-24.14%
6 months-37.14%
Current year-22.35%
More quotes
1 week
3.12
Extreme 3.115
3.80
1 month
3.12
Extreme 3.115
4.40
Current year
3.12
Extreme 3.115
8.50
1 year
3.02
Extreme 3.02
50.00
3 years
3.02
Extreme 3.02
190.00
5 years
3.02
Extreme 3.02
250.00
10 years
3.02
Extreme 3.02
250.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14/08/22
Director of Finance/CFO 49 23/08/23
Chairman 65 31/12/05
Members of the board TitleAgeSince
Director/Board Member 68 31/12/06
Chairman 65 31/12/05
Chief Tech/Sci/R&D Officer 47 31/12/01
More insiders
Date Price Change Volume
30/04/24 3.3 -7.04% 2 143 352
29/04/24 3.55 -2.74% 340,618
26/04/24 3.65 -2.67% 167,778
25/04/24 3.75 0.00% 220,253
24/04/24 3.75 -1.32% 187,413

Delayed Quote London S.E., April 30, 2024 at 01:32 pm

More quotes
Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.
More about the company

Quarterly revenue - Rate of surprise